ANDREW ROGERS PROFIAD YN HWYR YN EI YRFA I FYFYRIWR YMCHWIL Cymerais y llwybr hir i gychwyn ar fy ymchwil ar gyfer PhD. Dechreuodd y siwrnai drwy weithio am bum mlynedd ar hugain mewn Iechyd Cyhoeddus; symud i’r sector preifat fel ymgynghorydd busnes; ambell i daith i weithio gyda Sefydliad Iechyd a Byd neu’r Cenhedloedd… Darllen mwy »
MIRAIN LLWYD ROBERTS CYDLYNYDD PONTIO’R CENEDLAETHAU, CYNGOR GWYNEDD Pwrpas fy mhrosiect oedd edrych ar yr heriau a’r rhwystrau sy’n wynebu prosiectau pontio’r cenedlaethau. Teitl yr ymchwil oedd: “Pontio’r bobl a’r gymuned: Y rhwystrau a’r heriau sy’n wynebu prosiectau pontio’r cenedlaethau gan ganolbwyntio ar gynaliadwyedd”. Daeth sawl rhwystr a her i’r amlwg yn ystod yr ymchwil… Darllen mwy »
EMMA SAMUEL SAFBWYNT MYFYRIWR Mae’n ddyletswydd ar fusnesau bwyd i sicrhau bod y bwyd maen nhw’n ei baratoi i bobl ei fwyta yn ddiogel. Un o’r ffyrdd symlaf a mwyaf effeithiol o gyflawni hyn yw trwy gynnal arferion hylendid dwylo rhagorol wrth gynhyrchu bwyd. Fodd bynnag, mae ymchwil yn dangos, am lu o resymau, bod… Darllen mwy »
Ymddiheurwn, nid ar gael yn y Gymraeg. Peripheral Arterial Disease (PAD) is the less well-known branch of cardiovascular disease which relates to the narrowing or obstruction of the arteries in the legs. Previous research has shown that individuals with PAD have a three-to-six-fold increased risk of cardiovascular death compared to those who don’t have it. The main… Darllen mwy »
Over the past decade the ‘superbug’, Clostridium difficile, has become the most common hospital acquired infection in the developed world. Epidemic strains have emerged which exhibit enhanced virulence factors including multidrug resistance, increased capacity to form highly resistant spores and produce significantly more toxins A and B than conventional strains. This project with MicroPharm, a small bio-pharmaceutical company based in West Wales, looks at recombinant fragments based on C. difficile toxins A and B that have been used to raise antibodies in sheep.
Darllen mwy »
© 2023 KESS 2.